See more : Silvercorp Metals Inc. (0QZ2.L) Income Statement Analysis – Financial Results
Complete financial analysis of ClearPoint Neuro, Inc. (CLPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ClearPoint Neuro, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Guizhou Tyre Co.,Ltd. (000589.SZ) Income Statement Analysis – Financial Results
- ALIAXIS (BE0941243520.BR) Income Statement Analysis – Financial Results
- Albaad Massuot Yitzhak Ltd (ALBA.TA) Income Statement Analysis – Financial Results
- Metgasco Limited (MEL.AX) Income Statement Analysis – Financial Results
- Atai Life Sciences N.V. (ATAI) Income Statement Analysis – Financial Results
ClearPoint Neuro, Inc. (CLPT)
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.96M | 20.55M | 16.30M | 12.83M | 11.22M | 7.35M | 7.38M | 5.75M | 4.59M | 3.60M | 3.93M | 5.06M | 3.82M | 2.67M |
| Cost of Revenue | 10.34M | 7.02M | 5.01M | 3.71M | 3.83M | 2.43M | 2.90M | 2.64M | 1.99M | 1.93M | 1.42M | 555.70K | 656.41K | 16.31K |
| Gross Profit | 13.61M | 13.53M | 11.29M | 9.12M | 7.38M | 4.92M | 4.48M | 3.11M | 2.61M | 1.68M | 2.51M | 4.50M | 3.16M | 2.65M |
| Gross Profit Ratio | 56.83% | 65.84% | 69.27% | 71.09% | 65.83% | 66.91% | 60.72% | 54.03% | 56.74% | 46.53% | 63.84% | 89.01% | 82.81% | 99.39% |
| Research & Development | 11.71M | 10.89M | 8.99M | 4.69M | 2.92M | 2.31M | 2.81M | 2.63M | 1.96M | 3.30M | 2.92M | 1.60M | 4.25M | 5.68M |
| General & Administrative | 11.76M | 9.61M | 8.76M | 5.27M | 4.30M | 4.33M | 4.05M | 4.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.60M | 9.36M | 6.92M | 5.38M | 4.76M | 3.53M | 3.96M | 3.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.35M | 18.97M | 15.68M | 10.65M | 9.06M | 7.86M | 8.00M | 7.97M | 8.37M | 8.04M | 7.06M | 6.03M | 4.83M | 4.70M |
| Other Expenses | 0.00 | -22.00K | -63.00K | 882.00K | 9.05K | 364.00 | 16.68K | 216.08K | 230.88K | 1.80M | 863.79K | 2.80K | 104.85K | 413.62K |
| Operating Expenses | 36.06M | 29.86M | 24.67M | 15.34M | 11.98M | 10.17M | 10.82M | 10.60M | 10.33M | 11.34M | 9.98M | 7.63M | 9.08M | 10.38M |
| Cost & Expenses | 46.40M | 36.88M | 29.67M | 19.05M | 15.81M | 12.60M | 13.72M | 13.24M | 12.32M | 13.26M | 11.41M | 8.19M | 9.74M | 10.40M |
| Interest Income | 386.00K | 81.00K | 973.00K | 1.44M | 955.00K | 0.00 | 0.00 | 8.81K | 16.46K | 11.62K | 24.54K | 14.15K | 3.48K | 10.40K |
| Interest Expense | 0.00 | 81.00K | 973.00K | 1.44M | 955.17K | 980.38K | 872.93K | 1.06M | 1.26M | 1.01M | 475.30K | 2.58M | 2.50M | 1.59M |
| Depreciation & Amortization | 1.46M | 777.00K | 692.00K | 550.00K | 250.56K | 109.44K | 116.45K | 155.71K | 211.95K | 377.26K | 426.18K | 416.97K | 354.89K | 266.22K |
| EBITDA | -20.99M | -15.58M | -12.75M | -4.79M | -4.33M | -5.07M | -6.18M | -6.85M | -6.97M | -3.13M | -6.16M | -2.70M | -5.46M | -7.60M |
| EBITDA Ratio | -87.62% | -75.80% | -78.19% | -37.30% | -38.64% | -69.87% | -84.05% | -123.63% | -158.07% | -217.95% | -168.19% | -61.81% | -145.70% | -279.09% |
| Operating Income | -22.45M | -16.33M | -13.37M | -6.22M | -4.59M | -5.25M | -6.34M | -7.49M | -8.97M | -5.32M | -7.47M | -3.13M | -5.92M | -9.52M |
| Operating Income Ratio | -93.70% | -79.47% | -82.05% | -48.48% | -40.95% | -71.37% | -85.86% | -130.25% | -195.34% | -147.61% | -190.17% | -61.87% | -155.09% | -356.45% |
| Total Other Income/Expenses | 357.00K | -103.00K | -1.04M | -562.00K | -945.79K | -915.70K | -831.52K | -581.16K | 524.86K | 795.89K | 388.50K | -2.58M | -2.39M | 61.06K |
| Income Before Tax | -22.09M | -16.44M | -14.41M | -6.78M | -5.54M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Income Before Tax Ratio | -92.21% | -79.97% | -88.41% | -52.86% | -49.39% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| Income Tax Expense | 0.00 | 103.00K | 910.00K | 2.33M | 964.22K | 64.68K | 889.61K | 1.28M | 1.49M | 2.43M | 912.90K | 2.17M | 2.50M | 1.59M |
| Net Income | -22.09M | -16.54M | -15.32M | -9.11M | -6.50M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Net Income Ratio | -92.21% | -80.47% | -93.99% | -71.00% | -57.98% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| EPS | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| EPS Diluted | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| Weighted Avg Shares Out | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
| Weighted Avg Shares Out (Dil) | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery...
ClearPoint Neuro: Near-Term Volatility Is No Concern
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity...
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street...
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago.
ClearPoint Neuro Reports Third Quarter 2024 Results
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise...
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results...
ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock?
ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ClearPoint Neuro Announces Early Repayment of $10 Million Note
ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics
ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)
ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to...
Source: https://incomestatements.info
Category: Stock Reports